drug related crimes,
Smallest Geographic Unit:
District of Columbia,
New York (state),
New York City,
Date of Collection:
Unit of Observation:
All adult male arrestees age 18 and above at 10 geographically diverse locations between 2000 to 2003 and 2007 to 2010: Atlanta, Charlotte, Chicago, Denver, Indianapolis, Manhattan, Minneapolis, Portland Oregon, Sacramento, and Washington DC.
program source code
Data Collection Notes:
In order to use the SPSS syntax files provided in this collection, users must first obtain the following studies from the Arrestee Drug Abuse Monitoring (ADAM) Program/Drug Use Forecasting (DUF) Series: 2000 (ICPSR 3270), 2001 (ICPSR 3688), 2002 (ICPSR 3815), 2003 (ICPSR 4020), 2007 (ICPSR 25821), 2008 (ICPSR 27221), 2009 (ICPSR 30061), and 2010 (ICPSR 32321) available from the ICPSR Web site.
The data from the Arrestee Drug Abuse Monitoring (ADAM) Program/Drug Use Forecasting (DUF) Series are restricted from general dissemination. The ADAM collection may not be used for any purpose other than statistical reporting and analysis. Use of the ADAM data to learn the identity of any person or establishment is prohibited. To protect respondent privacy, these data are restricted from general dissemination. To obtain these files, researchers must agree to the terms and conditions of a Restricted Data Use Agreement in accordance with existing ICPSR servicing policies.
The purpose of this study was to examine the local nature of drug epidemics and drug markets. Specifically, the study had two objectives:
- Describe the natural course of the drug problems since 2000 through to the expected near-term future in the 10 jurisdictions served by ADAM II.
- Evaluate over time the relationships between the changing organization and operation of local drug markets and the direction and course of local drug epidemics, particularly with regard to the possible impact of law enforcement initiatives.
This study analyzed drug epidemics and analyzed changes in drug markets over time using the 37,933 adult male arrestees age 18 and above who provided urine samples from the 10 locations participating in ADAM II. The ADAM program approached a representative sample of arrestees awaiting booking within 48 hours of their arrest at each participating location and asked them to complete a 20-25 minute survey and provide a urine sample. They were offered a small incentive for participation. The ADAM program performed urine tests to obtain an objective measure of recent drug use not subject to respondents' lack of full and accurate disclosure.
The project obtained the ADAM 2000-2003 and the ADAM II 2007-2010 data from the National Archive of Criminal Justice Data (NACJD). Because of the gap between the ADAM and ADAM II programs, there are no data available for three years, 2004-2006. The 2010 data did not become available until November 2011, after all of the analyses had been completed. The study applied for and obtained an extension to this study in order to update analyses. All analyses of the drug epidemics were redone in order to cover 2000-2010. The analyses of drug markets where not revised; they cover 2000-2009.
The study evaluated trends in marijuana, crack, heroin, and methamphetamine at each of the ten ADAM II locations using a drug epidemics framework. The analyses of heroin and methamphetamine trends are limited to the ADAM sites that have had higher levels of use of these drugs. The analysis also examined the use of cocaine powder in contrast to crack cocaine at the five locations most affected by powder cocaine use.
The following three approaches were used to analyze ADAM drug market variables:
- Micro-data: Reliability and factor analysis of how market structure variables tend to be associated at the level of the individuals' experience.
- Site-Year Aggregated data: Reliability and factor analysis of the systematic variation in drug market variables over time and across locations.
- Trend analysis: Visual inspection of the variation in each drug market variable at each site over time comparing the trend to the course of prevailing drug epidemics.
This study used the 37,933 adult male arrestees age 18 and above who provided urine samples from the 10 locations (Atlanta, Charlotte, Chicago, Denver, Indianapolis, Manhattan, Minneapolis, Portland Oregon, Sacramento, and Washington DC) participating in ADAM II.
The ADAM program uses censuses and propensity scoring to develop sample weights. Sample weights for each location for each year were renormalized so that the sum of all weights equaled the number of cases. This assured that the multi-year analysis would give the appropriate weight to data collected in any given year proportional to the number of cases collected. These weights were used in all statistical calculations to provide unbiased estimates for the target population of adult male arrestees at each location.
ARRESTEE DRUG ABUSE MONITORING (ADAM) PROGRAM IN THE UNITED STATES, 2000 (ICPSR 3270)
ARRESTEE DRUG ABUSE MONITORING (ADAM) PROGRAM IN THE UNITED STATES, 2001 (ICPSR 3688)
ARRESTEE DRUG ABUSE MONITORING (ADAM) PROGRAM IN THE UNITED STATES, 2002 (ICPSR 3815)
ARRESTEE DRUG ABUSE MONITORING (ADAM) PROGRAM IN THE UNITED STATES, 2003 (ICPSR 4020)
ARRESTEE DRUG ABUSE MONITORING PROGRAM II IN THE UNITED STATES, 2007 (ICPSR 25821)
ARRESTEE DRUG ABUSE MONITORING PROGRAM II IN THE UNITED STATES, 2008 (ICPSR 27221)
ARRESTEE DRUG ABUSE MONITORING PROGRAM II IN THE UNITED STATES, 2009 (ICPSR 30061)
ARRESTEE DRUG ABUSE MONITORING PROGRAM II IN THE UNITED STATES, 2010 (ICPSR 32321)
Description of Variables:
Key variables used in the analyses of drug epidemics and drug markets as part of this study include demographic variables, arrest variables, drug variables, and drug market experiences variables. The demographic variables include: age, race, education, employment, and marital status. The arrest variables include: current arrest charge, and charge severity. Drug variables include: urine test results, lifetime drug use, age at first drug use, past year drug use, past month drug use, and past 72 hour drug use. Drug market experiences variables include: types of purchases, non-cash exhange for credit, contact method, use of courier, purchase location, purchase failure, number of dealers in past 30 days, relationship with dealer, and neighborhood of cash purchase.
From 2000 to 2010, 75-86 percent of selected respondents that were available agreed to participate and 77-91 percent of those provided urine samples.